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improvement	 in	 life	 expectancy,	 particularly	 among	 patients	 with	
conditions	 predisposing	 to	 venous	 thromboembolism	 (VTE),	 such	
as	cancer,	chronic	obstructive	pulmonary	disease,	and	autoimmune	
diseases,	may	 partly	 explain	 this	 finding	 in	most	 countries.	Other	
factors	 explaining	 this	 trend	 include	 the	broader	 adoption	of	 vali-




standardized	mortality	from	PE13 have been decreasing or plateau-
ing	over	 the	past	 years,	 possibly	 reflecting	 the	greater	proportion	
of	“low-	risk”	cases	being	diagnosed	and	an	improvement	in	PE	man-


















Introduction: Pulmonary	 embolism	 (PE)	 has	 not	 been	 accounted	 for	 as	 a	 cause	 of	
death	contributing	to	cause-	specific	mortality	in	global	reports.
Methods: We	 analyzed	 global	 PE-	related	mortality	 by	 focusing	 on	 the	 latest	 year	
available	 for	 each	member	 state	 in	 the	World	Health	Organization	 (WHO)	mortal-
ity	database,	which	provides	age-	sex–	specific	aggregated	mortality	data	transmitted	
by	national	authorities	 for	each	underlying	cause	of	death.	PE-	related	deaths	were	
defined	by	 International	Classification	of	Diseases,	 Tenth	Revision	 codes	 for	 acute	
PE	or	nonfatal	manifestations	of	venous	thromboembolism	 (VTE).	The	2001	WHO	
standard	population	served	for	standardization.
Results: We	 obtained	 data	 from	 123	 countries	 covering	 a	 total	 population	 of	
2	602	561	422.	Overall,	50	(40.6%)	were	European,	39	(31.7%)	American,	13	(10.6%)	
Eastern	Mediterranean,	13	 (10.6%)	Western	Pacific,	 3	 (2.4%)	Southeast	Asian,	 and	
2	 (1.6%)	African.	Of	 116	 countries	 classifiable	 according	 to	 population	 income,	 57	
(49.1%)	were	high	income,	42	(36.2%)	upper-	middle	income,	14	(12.1%)	lower-	middle	
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Global	 awareness	 campaigns,	 notably	 the	 World	 Thrombosis	
Day	initiative,	alert	the	general	public,	physicians,	and	stakeholders	
to the burden of thrombosis and promote broad implementation of 
available management strategies.21 The gap in global recognition 






are available from epidemiologic analyses and cohort studies.24-	27
A	 large	and	comprehensive	overview	of	global	PE-	related	mor-
tality	may	help	researchers	to	study	differences	in	reports,	identify	
priorities	 in	 VTE	 management,	 guide	 policy	 makers	 in	 designing	









death listed in death certificates and transmitted annually by deputed 














tributing cause.30 The present analysis aimed to provide an overview 
of	updated	statistics	on	PE-	related	mortality.	Therefore,	we	focused	
on	the	latest	year	available	in	the	WHO	mortality	database	for	each	
country or territory after the year 2000.
We	categorized	states	 in	six	regions	as	 indicated	by	the	WHO:	
African	 Region,	 Region	 of	 the	 Americas,	 Southeast	 Asia	 Region,	
European	 Region,	 Eastern	 Mediterranean	 Region,	 and	 Western	





ated	 homogeneous	 5-	year	 age	 groups	 up	 to	 85	 years	 old.	 Annual	
mortality	 data	 were	 provided	 as	 crude	 and	 age-	standardized	 PE-	
related	 mortality	 rates	 for	 the	 latest	 available	 year,	 expressed	 as	
the	number	of	PE-	related	deaths	in	each	age	group	by	the	total	cor-
responding 100 000 population of men and women. The updated 






related deaths in some states. To assess the presence of correlation 
between	 income	 level	and	age-	standardized	mortality	and	propor-
tionate	mortality	 rates,	 respectively,	we	used	a	 logistic	 regression,	
setting the income level as the independent variable.
We	followed	the	Guidelines	for	Accurate	and	Transparent	Health	
Estimates	Reporting	standards.34 This study did not need ethics or 
institutional review board approval because it did not include inter-








related	 death	 in	 a	way	 comparable	 to	 the	 other	 states	 (Table	 S1).	
Finally,	12	member	 states	were	excluded	because	 their	 age	group	
definition was not compatible with that of the other states.
Of the 123 member states or territories included in the anal-
ysis,	 50	 (40.6%)	were	 European,	 39	 (31.7%)	American,	 13	 (10.6%)	
Eastern	 Mediterranean,	 13	 (10.6%)	 Western	 Pacific,	 3	 (2.4%)	
Southeast	 Asian,	 and	 2	 (1.6%)	 African.	 Three	 (Mayotte,	 Reunion,	
and	Rodrigues)	could	not	be	classified	in	any	WHO	region.	Data	on	
population	size,	total	annual	deaths,	and	PE-	related	deaths	were	col-




Income	 categorization	 based	 on	 reference	 tables	was	 possible	
for	116	states:	Of	these,	57	 (49.1%)	were	high	 income,	42	 (36.2%)	
upper-	middle	income,	14	(12.1%)	lower-	middle	income,	and	3	(2.6%)	
low income. The proportion of states with available mortality data 
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high-	income	countries,	27	of	42	(64.3%)	upper-	middle	income,	7	of	
14	(50.0%)	lower-	middle	income,	and	1	of	3	(33.3%)	low	income.
This analysis covered a total of 2 602 561 422 general popula-
tion.	The	total	number	of	deaths	recorded	was	18	726	382,	of	which	
86	930	(0.46%)	had	been	primarily	attributed	to	PE	according	to	the	
death certificates. The country with the largest population was the 
United	States,	with	nearly	160	million	men	and	164	million	women	in	
2017. The country with the smallest population was Rodrigues with 
20 947 men and 21 691 women in 2017.
Tables	 S2	 and	 S3	 show	 population	 size,	 number	 of	 PE-	related	
death,	 crude	 PE-	related	mortality	 by	 age	 group	 and	 in	 the	 entire	
population,	and	age-	standardized	PE-	related	mortality	based	on	the	
2001	world	standard	population	in	women	and	in	men,	respectively.	
PE-	related	mortality	 rate	 increased	with	 age	with	 few	exceptions,	
F I G U R E  1 Overview	of	global	age-	standardized	PE-	related	mortality	in	women	and	men.	PE,	pulmonary	embolism
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mostly	 less	 populated	 states	 with	 a	 low	 absolute	 number	 of	 PE-	
related deaths. Figure 1 provides a visual overview of the global 
age-	adjusted	 PE-	related	 mortality	 in	 women	 and	 men.	 Figures	 2	
and	 3	 show	 the	 relationship	 of	 country	 income	 status	 with	 age-	
standardized	mortality	rates	and	proportionate	mortality	rates,	re-
spectively,	in	both	sexes.
In	 women,	 an	 age-	standardized	 PE-	related	 mortality	 <1.0	
death	 per	 100	 000	 population-	years	 was	 recorded	 in	 Haiti,	
Honduras,	 Peru,	Morocco,	 Tajikistan,	 Former	Yugoslav	Republic	
of	 Macedonia,	 Thailand,	 Brunei,	 Hong	 Kong,	 Japan,	 Kiribati,	
Mongolia,	 Philippines,	 Republic	 of	 Korea,	 Singapore,	 and	
Rodrigues.	In	men,	an	age-	standardized	PE-	related	mortality	<1.0	
deaths	 per	 100	 000	 population-	years	 was	 recorded	 in	 Aruba,	
Haiti,	 Honduras,	 Peru,	 Virgin	 Islands,	 Bahrain,	 Iraq,	 Lebanon,	
Morocco,	Malta,	 Tajikistan,	Maldives,	 Sri	 Lanka,	Thailand,	Hong	
Kong,	Japan,	Kiribati,	New	Zealand,	Republic	of	Korea,	Singapore,	
and	Solomon	Islands.
In	 women,	 an	 age-	standardized	 PE-	related	 mortality	 >10.0	
deaths	per	100	000	population-	years	was	recorded	in	Antigua	and	
Barbuda,	 Bahamas,	 Barbados,	 and	 Saint	 Vincent	 and	 Grenadines.	
In	men,	an	age-	standardized	PE-	related	mortality	>10.0	deaths	per	






Excluding	 member	 states	 not	 reporting	 any	 PE-	related	 death,	
the	highest	proportionate	PE-	related	mortality	rate	among	women	
was	recorded	in	Saint	Vincent	and	Grenadines	(3.3%)	and	Bahamas	
(3.2%),	 the	 lowest	was	 in	 Tajikistan,	which	 reported	 only	 one	 PE-	
related	death.	In	women,	PE	was	listed	as	the	underlying	cause	of	>1%	
of	overall	deaths	in	Aruba,	Bahamas,	Barbados,	Brazil,	Guadeloupe,	
Jamaica,	 Martinique,	 Lithuania,	 Luxembourg,	 Slovakia,	 United	
Kingdom,	Trinidad	and	Tobago,	Saudi	Arabia,	Tunisia,	Bulgaria,	Czech	
Republic,	Solomon	Islands,	and	Mayotte.
The	 highest	 proportionate	 PE-	related	 mortality	 rate	 among	
men	was	 recorded	 in	Antigua	 and	Barbuda	 (3.6%)	 and	 the	 lowest	
in	Sri	Lanka	(0.1%).	In	men,	PE	was	listed	as	the	underlying	cause	of	
>1%	of	overall	deaths	in	Antigua	and	Barbuda,	Bahamas,	Barbados,	
Martinique,	 Saint	 Vincent	 and	 Grenadines,	 Bulgaria,	 and	 Czech	
Republic.	 In	 both	 sexes,	 the	 contribution	 of	 PE	 to	 total	 mortality	
peaked	in	adults	aged	20	to	49	years.
Linear	 regression	 modeling	 showed	 a	 positive	 correlation	 be-





We	 provide	 a	 comprehensive	 overview	 of	 global	 PE-	related	
mortality,	 as	 reported	 in	 national	 vital	 registries	 of	 123	 states	
F I G U R E  2 Age-	standardized	mortality	rate	by	country	income	class	in	men	and	women.	Jittered	plot	of	the	distribution	of	the	age-	
adjusted	pulmonary	embolism-	related	mortality	rate	by	country	income	class.	Each	dot	represents	one	country.	The	fitted	regression	line	
(with	95%	confidence	interval)	is	shown	of	the	association	between	income	class	and	mortality	rate.	PE,	pulmonary	embolism
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or	 territories	 covering	>2.6	billion	 general	 population	 in	Europe,	
North	 and	 South	 America,	 Eastern	 Mediterranean,	 Western	
Pacific,	 Southeast	Asia,	 and	Africa.	 Several	 of	 our	 findings	 have	
the	 potential	 to	 trigger	 calls	 for	 action	 by	 health	 organizations,	
policy	makers,	and	the	thrombosis	research	community.	First,	re-
ported	deaths	were	 characterized	by	 large	heterogeneity	 across	
regions	and	states,	which	is	unlikely	to	be	solely	explained	by	dif-
ferent	 socioeconomic	 characteristics,	 management	 practices,	 or	
prevalence	 of	 risk	 factors.	Differences	 in	 the	 accuracy	 of	 cause	
of	death	reporting	are	indeed	likely	and	should	be	taken	into	ac-
count. These differences may originate from local clinical and 






in	 earlier	 studies,13,30 but also in other geographic regions. This 
generalized	inequality	calls	for	dedicated	studies	and	tailored	rec-




larly	 in	 high-	income	 countries,	may	 partly	 explain	 these	 results.	
Third,	PE	mortality	was	highest	among	older	adults	in	both	high-	
and	 low-	income	 states,	 which	 highlights	 the	 paucity	 of	 higher-	
quality	 thrombosis	management	studies	 in	 the	elderly.	Finally,	 in	
addition	 to	 abating	 the	 burden	 of	 VTE-	associated	 death,	 broad	












In the absence of data from national reports and global epidemi-
ologic	studies,	we	performed	a	cross-	sectional	study	that	provides	
a	 global	 overview	 of	 the	 recent	 PE-	related	 mortality	 information	
by	 systematic	analysis	of	data	 from	 the	WHO	mortality	database.	
Our	 global	 approach	 addressed	 the	 lack	 of	 data	 from	many	 non–	
high-	income	 states,	 as	 previously	 observed	 by	 the	 ISTH	 Steering	
Committee	for	World	Thrombosis	Day.14 In regions with a high pro-
portion	of	 low-	or	 lower-	middle-	income	countries,	data	were	con-






F I G U R E  3 Proportionate	PE-	related	mortality	by	country	income	class	in	men	and	women.	Jittered	plot	of	the	distribution	of	PE-	related	
proportionate	mortality	by	country	income	class.	Each	dot	represents	one	country.	The	fitted	regression	line	(with	95%	confidence	interval)	
is	shown	of	the	association	between	income	class	and	proportionate	mortality.	PE,	pulmonary	embolism
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is	often	highest	in	people	aged	20	to	49	years	of	both	sexes.	In	con-
trast,	 in	 low-	income	 states	 it	 tends	 to	 be	 highest	 in	 older	 people,	
especially	 in	men.	 A	 longer	 life	 expectancy	 in	 high-	income	 states	
may	 lead	 to	higher	prevalence	of	comorbidities,	 such	as	cancer	or	
cardiovascular	disease,	which	contribute	to	death	more	than	PE	and	
effectively	 serve	 as	 a	 competing	 risk.	 In	 low-	income	 states,	 infec-
tious	diseases,	maternal	and	neonatal	conditions,	and	injuries14 are 
a leading cause of mortality. Only survivors who reach older age are 
exposed	 to	noncommunicable	diseases	 such	as	VTE.	This	may	ex-
plain	why	PE	mortality	 is	highest	among	older	adults.	However,	 in	
recent	 years,	 low-	income	 states	 experienced	 a	 transition	 from	 in-
fectious diseases to noncommunicable diseases as major causes of 
death and disability.14	 In	 several	 countries,	 noncommunicable	 dis-
eases and years lived with disability accounted for more than half of 
the entire disease burden in 2019.14	As	a	result,	much	more	attention	
to	VTE	is	warranted	worldwide.
One	consequence	of	the	2020	coronavirus	pandemic	was	an	in-
crease in acute thromboembolic complications.42,43 Due to its dis-
tinctly	prothrombotic	phenotype,44	COVID-	19	 is	 likely	 to	 increase	
PE-	related	mortality.	This	underlines	the	need	for	more	rapid	global	
implementation	 of	 evidence-	based	 preventive	 and	 therapeutic	
measures.	 Indeed,	thrombosis	associated	with	COVID-	19	 infection	
may	 reverse	 the	 overall	 decreasing	 trend	 in	 PE-	related	 mortality	
observed	 in	the	European	Region,	United	States,	and	Canada	over	
the past 15 to 20 years.42	VTE	 is	 largely	preventable,	 and	 several	
randomized	 controlled	 trials	 are	 currently	 under	 way	 to	 evaluate	
thromboprophylaxis	in	COVID-	19	infection,	in	both	ambulatory	and	
hospital settings.45,46
Awareness	 of	 PE	 continues	 to	 be	 low:	 a	 survey	 by	 World	
Thrombosis	 Day	 (WTD)	 in	 2014	 showed	 that	 50%	 of	 people	 are	
not aware of or have never heard the term pulmonary embolism.14 
International	programs	such	as	the	WTD	and	the	WHO’s	Thirteenth	
General	Program	of	Work	2019–	2023	aim	to	reduce	mortality	due	to	
noncommunicable disease by promoting a comprehensive approach 
that	 includes	 timely	 prevention	 and	 diagnosis.	 Public	 awareness	
plays	a	key	role	in	the	implementation	of	these	programs.14
Our	study	has	some	limits.	First,	the	attribution	of	deaths	to	PE	









conclusions drawn from the available data may not be accurate. 
Third,	our	 study	was	cross	 sectional	and	did	not	allow	 for	evalua-
tion	of	 trends	over	 time.	Fourth,	data	 for	 two	of	 the	world’s	most	
populated	states,	China	and	 India,	were	not	available	 in	 the	WHO	
mortality	database.	However,	the	availability	of	data	from	123	states	
and	territories	on	six	continents	covering	more	than	one-	third	of	the	
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